KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Accounts Payables: 2018-2025

Historic Accounts Payables for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $2.2 million.

  • Aurinia Pharmaceuticals' Accounts Payables fell 96.10% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 96.10%. This contributed to the annual value of $5.2 million for FY2024, which is 19.88% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Accounts Payables stood at $2.2 million, which was down 33.15% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Accounts Payables registered a high of $56.8 million during Q3 2024, and its lowest value of $2.2 million during Q3 2025.
  • For the 3-year period, Aurinia Pharmaceuticals' Accounts Payables averaged around $28.4 million, with its median value being $36.0 million (2023).
  • In the last 5 years, Aurinia Pharmaceuticals' Accounts Payables skyrocketed by 89.36% in 2021 and then tumbled by 96.10% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Accounts Payables stood at $34.9 million in 2021, then climbed by 14.43% to $40.0 million in 2022, then plummeted by 89.18% to $4.3 million in 2023, then increased by 19.88% to $5.2 million in 2024, then slumped by 96.10% to $2.2 million in 2025.
  • Its Accounts Payables was $2.2 million in Q3 2025, compared to $3.3 million in Q2 2025 and $4.2 million in Q1 2025.